Class summary at a glance.

Every drug in the Catechol-O-Methyltransferase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $53.1Mcombined across class
Total Rx claims: 224K54K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Entacapone

198K Part D claims (CY24) · 48K beneficiaries · First FDA approval: 2013-04-01

7 generic mfrs 0 plans require PA

Low NADAC$0.360

→

Avg plan cost$0.360

Part D spend $29.0M 1× spread, current vs floor

Class share

55%

of class CY24 spend

View profile →

Opicapone

Brand: ONGENTYS · 25K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2024-04-05

Brand-only (no generics) 16 plans require PA

Low NADAC$24.67

→

Avg plan cost$24.71

Part D spend $23.4M 1× spread, current vs floor

Class share

44%

of class CY24 spend

View profile →

Tolcapone

Brand: Tasmar · 190 Part D claims (CY24) · 35 beneficiaries · First FDA approval: 2004-07-27

1 generic mfrs 4 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $689158

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.